There are site of care (SOC) restrictions that may impact where Neurolyxan (neurolyximab) can be administered. Specifically:
- Payers are pushing patients out of hospital outpatient infusion departments (HOPDs) to less expensive settings, such as physician offices or alternate infusion centers (AICs). This is achieved through SOC policies or specialty pharmacy (SP) mandates, which significantly affect where patients can or cannot receive Neurolyxan infusions
Neurolyxan PAVES (1).pdf.Neurolyxan PAVES (1).pdfParagraph of text that this answer was based on:They do this by putting in SOC policies or SP mandates. These policies have a significant effect on Neurolyxan and where patients can or can't be infused.Always refer to the live PAVES site at go.gene.com/PAVES for current information.PAVES Original PAVES...
- These policies are not specific to a single Cleveland Clinic site but are part of broader payer-driven efforts that could apply across all sites where Neurolyxan is administered
Neurolyxan PAVES (1).pdf.Neurolyxan PAVES (1).pdfParagraph of text that this answer was based on:These policies are not specific to any single site but are part of broader payer-driven efforts across all administration locations.PAVES Original PAVES...
No specific Cleveland Clinic site is mentioned in the documents, but the described SOC policies could influence administration logistics at any location.
